March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq ... which developed the FDA-approved CAR T-cell therapy Breyanzi ® for large B-cell lymphoma, until the company was sold to Celgene, ...

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) had its target price boosted by equities researchers at B. Riley from $20.00 to $24.00 in a note issued to investors on Wednesday ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) – Research analysts at B. Riley raised their FY2026 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a research ...

These increases were partially offset by decreased research and development costs due to the timing of clinical trial activities related to R289, Rigel's dual IRAK 1/4 inhibitor program ...

On the financial front, Rigel reported an expected total revenue of approximately $57.6 million for the fourth quarter of 2024, a substantial increase from the same period in 2023. The company's ...

Explore Rigel Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RIGL. Wall Street Awaits Trump's Tariff Decision, Digests Mixed Economic ...

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported fourth-quarter earnings of $14.3 million. On a per-share basis ...

Revenue: US$179.3m (up 55% from FY 2023). Net income: US$17.5m (up from US$25.1m loss in FY 2023). Profit margin: 9.8% (up from net loss in FY 2023). The move to profitability was driven by higher ...

Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the Fourth Quarter and Full Year 2024. [Operator Instructions] As a reminder, this conference is being recorded.

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results ...